Clinical trial
KYSA-8: A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
NCT06588491 is registered in ClinicalTrials.gov with Kyverna Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- KYSA-8: A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
- Lead sponsor
- Kyverna Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 25, 2024
- Completion date
- June 25, 2026
- Enrollment
- 27 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.